A Prospective, Randomized, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of GS-4059 and Idelalisib with and without Obinutuzumab in Subjects with Chronic Lymphocytic Leukemia
Phase of Trial: Phase II
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Idelalisib (Primary) ; Obinutuzumab (Primary) ; Tirabrutinib (Primary)
- Indications Lymphoid leukaemia
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 05 Apr 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Jun 2018.
- 03 Jan 2017 Status changed from not yet recruiting to recruiting.
- 22 Nov 2016 Planned End Date changed from 31 Aug 2022 to 1 Oct 2022.